Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 93-100

  Bonadonna, Gianni ^a   Valagussa, Pinuccia ^a   Brambilla, Cristina ^a   Ferrari, Laura ^a   Moliterni, Angela ^a   Terenziani, Monica ^a   Zambetti, Milvia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOXANTRONE;

ADULT; AGED; ARTICLE; AXILLA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0031972858     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.93     Document Type: Article

References (26)

1. Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127-2137, 1992
2. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 399:1-15, 71-85, 1992
3. Fisher B: The evolution of paradigms for the management of breast cancer: a personal perspective. Cancer Res 52:2371-2383, 1992
4. Early Breast Cancer Trialists' Collaborative Group: Effects of radiotherapy and surgery in early breast cancer: An overview of randomized trials. N Engl J Med 333:1444-1455, 1995
5. Valagussa P, Zambetti M, Bonadonna G, et al: Prognostic factors in locally advanced noninflammatory breast cancer: Long-term results following primary chemotherapy. Breast Cancer Res Treat 15:137-147, 1990
6. Hortobagyi GN, Singletary SE, McNeese MD: Treatment of locally advanced and inflammatory breast cancer, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott-Raven, 1996, pp 585-599
7. Feldman LD, Hortobagyi GN, Buzdar AU, et al: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46:2578-2581, 1986
8. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
9. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542-547, 1995
10. Veronesi U, Saccozzi R, Del Vecchio M. et al: Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancer of the breast. N Engl J Med 305:6-11, 1981
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Cox DR: Regression models and life tables (with discussion). J R Stat Soc [B] 34:187-220, 1972
13. Miller RC: Survival Analysis. New York, NY, Wiley, 1981
14. Kalbfleisch JD, Prentice RL: The Survival Analysis of Failure Time Data. New York, NY, Wiley, 1980
15. Bonadonna G, Valagussa P, Zucali R, et al: Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 45:227-243, 1995
16. Bonadonna G., Valagussa P: Primary chemotherapy in operable breast cancer. Semin Oncol 23:464-474, 1996
17. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
18. Recht A, Come SE, Henderson IC, et al: The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 334:1356-1361, 1996
19. Mauriac L, Durand M, Avril A, et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single center. Ann Oncol 2:347-354, 1991
20. Scholl SM, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast cancer conserving surgery. Preliminary results of a randomized trial: S6. Eur J Cancer 30A:645-652, 1994
21. Powels TJ, Hickish TF, Makris A, et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547-552, 1995
22. Semiglazov VF, Topuzov EE, Bavli JL, et al: Primary (neoadjuvant) chemotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5:591-595, 1994
23. Bonadonna G: Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute. Eur J Cancer 32A:209-214, 1996
24. Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43:1488-1492, 1983
25. Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
26. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-153, 1995